Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort ...
NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetingsEnrolled eight patients into ...
Apartment Investment and Management Company ("Aimco") announced today the conclusion of the strategic review process and third quarter results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback